Que voudriez-vous rechercher?
Site search
Filtres de recherche

Chambers Europe 2020 - Life Sciences

Christian Wyss covers a range of matters within the life sciences field, including licensing agreements and acquisitions. He also offers notable strength in financing mandates. One client describes him as "flexible and responsive," adding: "He is adaptable to the situation as needed in negotiations."

Legal 500 (EMEA 2019) - "Healthcare and Life Sciences" - Tier 1

"VISCHER is renowned for its expertise in corporate, commercial, transactional, regulatory and patent-related healthcare and biotech matters. Matthias Staehelin assisted Medartis with its initial public offering on the SIX Swiss Exchange, while Stefan Kohler acted for Novo Nordisk Pharma in its appeal against a pricing decision made by the Swiss Federal Office of Public Health concerning the client's type-two diabetes product. Christian Wyss advised Lundbeck on its €905m acquisition of Prexton Therapeutics."

Who's Who Legal (Switzerland 2019) - "Life Sciences"

"Stefan Kohler of Vischer is a well-known name in the Swiss market who possesses a strong reputation for his deep knowledge of IP regulation and contractual matters."

Chambers Europe (2019) - "Life Sciences" - Band 1

"Stefan Kohler has a strong track record in regulatory matters and is recognised for his expertise in pricing-related issues and market access questions. He assisted Philip Morris International with the regulatory and liability aspects of the launch of its new product IQOS. A source describes him as "confident and solution-oriented" and lauds his capabilities in the pharmaceutical industry."

Chambers Europe (2019) - "Life Sciences"

"Matthias Staehelin has significant experience in high-value transactional and financing work within the life sciences industry. His clients appreciate him for "his business acumen and ability to come up with practical solutions" and deem him to be a "pragmatic, assertive and solution-driven" practitioner."

Chambers Europe (2019) - "Life Sciences"

"A client describes Christian Wyss as "practical and knowledgeable" and another adds that "working with him is very easy and his responses are always on time." He acts for clients from the life sciences sector on financing and transactional matters, and assisted JSR Corporation with the Swiss aspects of its acquisition of Selexis. Wyss also advises on regulatory matters, such as research agreements and clinical trials."

Who's Who Legal (Switzerland 2018) - "Life Sciences"

"Stefan Kohler at VISCHER is a key player in the market who sources describe as 'an excellent patent litigator', adding that he is also 'very strong at handling regulatory matters'."

Legal 500 (EMEA 2018) - "Healthcare and life sciences" - Tier 1

"Vischer provides transactional, financing, capital markets, product launch and regulatory advice to health and life sciences industry clients and further represents them in contentious matters. The practice assisted JSR Corporation with its acquisition of Selexis and advised Axovant Sciences on its debt financing agreement with Hercules Capital. Stefan Kohler jointly heads the practice with Matthias Staehelin; Christian Wyss is another name to note."

Chambers Europe (2018) - "Life Sciences" - Band 1

"Highly regarded for its work assisting biotech companies with transactions, licensing and financing matters, including IPOs. Has a strong regulatory practice, advising on product compliance, liability risks, reimbursement pricing and therapeutic applications. Also represents clients in patent litigation and in agreement negotiations for clinical trials. Strengths One client enthuses that the team has 'strong insight and communicates well on legal strategy and possible outcomes.' Another source adds: 'The clarity of the advice and the speed of service were amazing.'"

Chambers Europe (2018) - "Life Sciences"

"Stefan Kohler is 'very open and approachable,' according to one source, who also notes that he is a 'good adviser.' He successfully represented Novo Nordisk Pharma in an appeal regarding pricing orders and has further experience relating to negotiations and the implementation of new regulations, as well as compliance and liability risk issues."